000287651 001__ 287651
000287651 005__ 20240328132827.0
000287651 0247_ $$2doi$$a10.1177/09622802241227951
000287651 0247_ $$2pmid$$apmid:38327081
000287651 0247_ $$2ISSN$$a0962-2802
000287651 0247_ $$2ISSN$$a1477-0334
000287651 037__ $$aDKFZ-2024-00294
000287651 041__ $$aEnglish
000287651 082__ $$a610
000287651 1001_ $$00000-0002-9266-4554$$aPepić, Amra$$b0
000287651 245__ $$aA diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II.
000287651 260__ $$aLondon [u.a.]$$bSage$$c2024
000287651 3367_ $$2DRIVER$$aarticle
000287651 3367_ $$2DataCite$$aOutput Types/Journal article
000287651 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711628861_22852
000287651 3367_ $$2BibTeX$$aARTICLE
000287651 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287651 3367_ $$00$$2EndNote$$aJournal Article
000287651 500__ $$a2024 Mar;33(3):433-448
000287651 520__ $$aThe development process of medical devices can be streamlined by combining different study phases. Here, for a diagnostic medical device, we present the combination of confirmation of diagnostic accuracy (phase III) and evaluation of clinical effectiveness regarding patient-relevant endpoints (phase IV) using a seamless design. This approach is used in the Thyroid HEmorrhage DetectOr Study (HEDOS & HEDOS II) investigating a post-operative hemorrhage detector named ISAR-M THYRO® in patients after thyroid surgery. Data from the phase III trial are reused as external controls in the control group of the phase IV trial. An unblinded interim analysis is planned between the two study stages which includes a recalculation of the sample size for the phase IV part after completion of the first stage of the seamless design. The study concept presented here is the first seamless design proposed in the field of diagnostic studies. Hence, the aim of this work is to emphasize the statistical methodology as well as feasibility of the proposed design in relation to the planning and implementation of the seamless design. Seamless designs can accelerate the overall trial duration and increase its efficiency in terms of sample size and recruitment. However, careful planning addressing numerous methodological and procedural challenges is necessary for successful implementation as well as agreement with regulatory bodies.
000287651 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000287651 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287651 650_7 $$2Other$$aSeamless design
000287651 650_7 $$2Other$$aadaptive design
000287651 650_7 $$2Other$$adiagnostic accuracy
000287651 650_7 $$2Other$$aexternal controls
000287651 650_7 $$2Other$$apower prior
000287651 7001_ $$aStark, Maria$$b1
000287651 7001_ $$00000-0001-5347-7441$$aFriede, Tim$$b2
000287651 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b3$$udkfz
000287651 7001_ $$0P:(DE-He78)b5d9469407737829d5348adb615655c6$$aCalderazzo, Silvia$$b4$$udkfz
000287651 7001_ $$aReichert, Maria$$b5
000287651 7001_ $$aWolf, Michael$$b6
000287651 7001_ $$aWirth, Ulrich$$b7
000287651 7001_ $$aSchopf, Stefan$$b8
000287651 7001_ $$00000-0002-8467-0508$$aZapf, Antonia$$b9
000287651 773__ $$0PERI:(DE-600)2001539-2$$a10.1177/09622802241227951$$gp. 09622802241227951$$n3$$p433-448$$tStatistical methods in medical research$$v33$$x0962-2802$$y2024
000287651 909CO $$ooai:inrepo02.dkfz.de:287651$$pVDB
000287651 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000287651 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b5d9469407737829d5348adb615655c6$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000287651 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000287651 9141_ $$y2024
000287651 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-10-22$$wger
000287651 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTAT METHODS MED RES : 2022$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000287651 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000287651 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000287651 980__ $$ajournal
000287651 980__ $$aVDB
000287651 980__ $$aI:(DE-He78)C060-20160331
000287651 980__ $$aUNRESTRICTED